Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Alex Soriano and Marta Bodro.
Alex Soriano
Connection Strength
2.166
Marta Bodro
  1. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. Am J Transplant. 2021 12; 21(12):3971-3979.
    View in: PubMed
    Score: 0.240
  2. Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19. J Clin Med. 2021 Apr 07; 10(8).
    View in: PubMed
    Score: 0.235
  3. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. Rev Esp Quimioter. 2021 Jun; 34(3):238-244.
    View in: PubMed
    Score: 0.235
  4. Increased CSF levels of IL-1ß, IL-6, and ACE in SARS-CoV-2-associated encephalitis. Neurol Neuroimmunol Neuroinflamm. 2020 09; 7(5).
    View in: PubMed
    Score: 0.223
  5. Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study. Antimicrob Agents Chemother. 2018 11; 62(11).
    View in: PubMed
    Score: 0.198
  6. [Clinical features and outcome in patients with mucormycosis in a tertiary hospital (2012-2016)]. Rev Iberoam Micol. 2018 Jul - Sep; 35(3):162-166.
    View in: PubMed
    Score: 0.197
  7. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018 06; 13:165-170.
    View in: PubMed
    Score: 0.188
  8. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam. Future Microbiol. 2017 11; 12:1323-1326.
    View in: PubMed
    Score: 0.184
  9. Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. J Antimicrob Chemother. 2021 11 12; 76(12):3296-3302.
    View in: PubMed
    Score: 0.061
  10. Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. BMJ Open. 2021 08 17; 11(8):e040775.
    View in: PubMed
    Score: 0.060
  11. Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. Infect Dis Ther. 2021 Sep; 10(3):1407-1418.
    View in: PubMed
    Score: 0.059
  12. Experience with the use of siltuximab in patients with SARS-CoV-2 infection. Rev Esp Quimioter. 2021 Aug; 34(4):337-341.
    View in: PubMed
    Score: 0.059
  13. Real-life use of remdesivir in hospitalized patients with COVID-19. Rev Esp Quimioter. 2021 Apr; 34(2):136-140.
    View in: PubMed
    Score: 0.058
  14. Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. Lancet Reg Health Eur. 2021 Apr; 3:100041.
    View in: PubMed
    Score: 0.058
  15. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021 Jan; 27(1):83-88.
    View in: PubMed
    Score: 0.056
  16. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020 05 16; 395(10236):e84.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.